title: Response to Linberg et al. Natalizumab alters transcriptional expression profiles of blood cell subpopulations of multiple sclerosis patients.
authors.forename: Sidney A
authors.initials: SA
authors.lastname: Houff
authors.forename: Joseph
authors.initials: J
authors.lastname: Berger
authors.forename: Eugene O
authors.initials: EO
authors.lastname: Major
mesh_terms: D000911:Antibodies, Monoclonal / Q000494:pharmacology* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D001773:Blood Cells / Q000187:drug effects* / Q000378:metabolism; D006801:Humans; D009103:Multiple Sclerosis / Q000097:blood / Q000188:drug therapy; D000069442:Natalizumab; D014158:Transcription, Genetic / Q000187:drug effects*
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000069442:Natalizumab